Hi, your posts on AVTR and the whole bioprocessing space are great!
Do you have further evidence of AVTR's share losses in bioprocessing other than the comparison with market growth? Is it possible that the products sold by AVTR are, on average, less critical (and face more competition) than the more complex stuff that the big boys are selling (Merck, Cytiva, Sartorius, TMO...) and therefore might face price deflation where the others are benefitting from 1-2% annual price increases?
In either case that's not good news for AVTR, but if AVTR is losing share of volumes it's in my opinion worse than suffering from natural deflation due to the nature of the niche they are paying in.
Hi, your posts on AVTR and the whole bioprocessing space are great!
Do you have further evidence of AVTR's share losses in bioprocessing other than the comparison with market growth? Is it possible that the products sold by AVTR are, on average, less critical (and face more competition) than the more complex stuff that the big boys are selling (Merck, Cytiva, Sartorius, TMO...) and therefore might face price deflation where the others are benefitting from 1-2% annual price increases?
In either case that's not good news for AVTR, but if AVTR is losing share of volumes it's in my opinion worse than suffering from natural deflation due to the nature of the niche they are paying in.
Cheers,